Axsome TherapeuticsNASDAQ: AXSM

Yes, bargains can still be found in the stock market.

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.

Axsome Therapeutics' revenue is growing rapidly. The company's pipeline should lead to many new approvals and label expansions.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.

Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losses despite revenue growth. Auvelity faces stiff competition in the depression market, with uncertain positioning and high marketing expenses.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of America Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners David Amsellem - Piper Sandler Joel Beatty - Baird Joseph Thome - TD Cowen David Hoang - Citigroup Graig Suvannavejh - Mizuho Securities Ashwani Verma - UBS Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Operator Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.